Its wide repertoire of oncogenic downstream targets such as NF-κB, Bcl-2, SLAMF7, or cyclin E2 suggests that MMSET inhibition could lead to anti-cancer effects in MM, via small molecules or siRNA delivery [17]. Here, BCL2 is linked to Miyoshi myopathy.